(3-methoxypyridazin-4-yl)methanamine | 1149586-23-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3-methoxypyridazin-4-yl)methanamine
• CAS: 1149586-23-1
• 化学式: C₆H₉N₃O
• 分子量: 139.157
• InChiKey: MHVFADAQUFNETM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3-methoxypyridazin-4-yl)methanamine 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-({[(1s,3R,4s,5S,7s)-4-aminoadamantan-1-yl]methyl}amino)-2-({[2-(methoxy)pyridazin-3-yl]methyl}amino)pyrimidine-5-carbonitrile
  参考文献：
  名称：

  Discovery of 2,4-diamino-5-cyanopyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions

  摘要：

  Protein kinase C theta (PKC theta) plays a critical role in T cell signaling and has therapeutic potential for T cell-mediated diseases such as transplant rejection and rheumatoid arthritis. PKC. inhibitors have emerged as effective immunomodulative agents for the prevention of transplant rejection. We previously reported that the 2,4-diamino-5-cyanopyrimidine derivative 2 was a potent PKC. inhibitor; however, it exhibited CYP3A4 time-dependent inhibition (TDI). Here, we report the structural modification of compound 2 into 34 focusing on mitigating CYP3A4 TDI. Compound 34 exhibited potent in vitro activity with mitigated CYP3A4 TDI and efficacy in vivo transplant model.

  DOI：

  10.1016/j.bmc.2019.01.019

文献信息

• [EN] PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDAZINONE ET LEUR UTILISATION COMME INHIBITEURS DU RÉCEPTEUR P2X7
  申请人：NISSAN CHEMICAL IND LTD

  公开号：WO2009057827A1

  公开（公告）日：2009-05-07

  Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.

  翻译结果为：新型的哒嗪酮化合物，其化学公式为(I)，能够抑制嘌呤能P2X7受体，并对预防、治疗和改善炎症性和免疫性疾病有益。
• Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods
  申请人：Lohmann Jan Klaas

  公开号：US20100077512A1

  公开（公告）日：2010-03-25

  The present invention relates to novel pyridazin-4-ylmethyl-sulfonamide compounds (I) and to their N-oxides, their agriculturally acceptable salts and their veterinarily acceptable salts and also to agricultural compositions comprising at least one such compound as active component, and also to their use for controlling harmful fungi. The present invention also relates to a method for controlling arthropod pests.

  本发明涉及新型吡啶并嗪-4-基甲基磺酰胺化合物(I)及其N-氧化物、其农业上可接受的盐和其兽医学上可接受的盐，以及至少包括一种该化合物作为活性成分的农业组合物，并且还涉及它们用于控制有害真菌的用途。本发明还涉及一种控制节肢动物害虫的方法。
• PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS
  申请人：Shigeta Yukihiro

  公开号：US20100286390A1

  公开（公告）日：2010-11-11

  Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.

  化合物(I)是一种新型的吡啶并嗪酮化合物，可以抑制嘌呤能P2X7受体，因此可用于预防、治疗和改善炎症和免疫性疾病。
• PYRIDAZIN-4-YLMETHYL-SULFONAMIDES USED AS FUNGICIDES AND AGAINST ARTHROPODS
  申请人：BASF SE

  公开号：EP2066643A1

  公开（公告）日：2009-06-10
• PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS
  申请人：Nissan Chemical Industries, Ltd.

  公开号：EP2203429A1

  公开（公告）日：2010-07-07